HCA Healthcare (NYSE:HCA) was downgraded by equities researchers at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating in a research report issued on Wednesday, January 3rd, MarketBeat reports. They currently have a $81.00 price objective on the stock. Piper Jaffray Companies’ price objective indicates a potential downside of 16.56% from the company’s previous close.
A number of other analysts have also commented on HCA. Robert W. Baird reissued a “buy” rating on shares of HCA Healthcare in a report on Thursday, September 28th. ValuEngine raised HCA Healthcare from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $90.00 price objective on shares of HCA Healthcare in a report on Thursday, October 19th. BMO Capital Markets started coverage on HCA Healthcare in a report on Monday, October 16th. They issued an “outperform” rating and a $90.00 price objective for the company. Finally, Mizuho reaffirmed a “buy” rating and issued a $92.00 price objective on shares of HCA Healthcare in a report on Wednesday, October 4th. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have issued a buy rating to the company’s stock. HCA Healthcare presently has a consensus rating of “Buy” and a consensus price target of $88.32.
HCA Healthcare (NYSE HCA) traded up $4.24 on Wednesday, hitting $97.07. The stock had a trading volume of 3,553,220 shares, compared to its average volume of 1,834,521. The stock has a market cap of $32,866.70, a PE ratio of 13.81, a PEG ratio of 1.21 and a beta of 0.55. HCA Healthcare has a 52 week low of $71.18 and a 52 week high of $97.12. The company has a current ratio of 1.68, a quick ratio of 1.41 and a debt-to-equity ratio of -6.46.
HCA Healthcare (NYSE:HCA) last announced its quarterly earnings data on Tuesday, October 31st. The company reported $1.21 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $1.21. The business had revenue of $10.70 billion during the quarter, compared to analysts’ expectations of $10.70 billion. HCA Healthcare had a negative return on equity of 47.16% and a net margin of 6.13%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.45 earnings per share. sell-side analysts predict that HCA Healthcare will post 6.56 EPS for the current fiscal year.
In other news, SVP Victor L. Campbell sold 8,000 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $75.82, for a total transaction of $606,560.00. Following the transaction, the senior vice president now owns 127,275 shares of the company’s stock, valued at $9,649,990.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Michael S. Cuffe sold 2,150 shares of the company’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $78.00, for a total value of $167,700.00. Following the transaction, the insider now directly owns 12,476 shares in the company, valued at approximately $973,128. The disclosure for this sale can be found here. Insiders have sold 20,550 shares of company stock worth $1,606,172 over the last three months. 2.90% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in HCA. Northwestern Mutual Wealth Management Co. grew its stake in HCA Healthcare by 14.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,163 shares of the company’s stock worth $101,000 after purchasing an additional 143 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its stake in HCA Healthcare by 35.1% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 1,232 shares of the company’s stock worth $107,000 after purchasing an additional 320 shares in the last quarter. Atlantic Trust LLC bought a new position in HCA Healthcare in the second quarter worth approximately $118,000. Acrospire Investment Management LLC grew its stake in HCA Healthcare by 14.3% in the second quarter. Acrospire Investment Management LLC now owns 1,600 shares of the company’s stock worth $140,000 after purchasing an additional 200 shares in the last quarter. Finally, BB&T Investment Services Inc. bought a new position in HCA Healthcare in the second quarter worth approximately $141,000. 75.34% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “HCA Healthcare (HCA) Downgraded by Piper Jaffray Companies to “Neutral”” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/28/hca-healthcare-hca-cut-to-neutral-at-piper-jaffray-companies.html.
About HCA Healthcare
HCA Healthcare, Inc, formerly HCA Holdings, Inc, is a holding company. The Company, through its subsidiaries, owns and operates hospitals and related healthcare entities. As of December 31, 2016, the Company operated in two geographically organized groups, including the National and American Groups. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia.
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.